Trending

Promacta

AbbVie’s Humira tops ICER’s list of unwarranted price hikes again

AbbVie’s Humira tops ICER’s list of unwarranted price hikes again

With drug pricing controls back on the legislative table in the US, the influential Institute for Clinical and

X

AbbVie’s Humira tops ICER’s list of unwarranted price hikes again

https://pharmaphorum.com/news/abbvies-humira-tops-icers-list-of-unwarranted-price-hikes-again/

Sobi gets EU nod for Doptelet in rare blood disorder ITP

Sobi gets EU nod for Doptelet in rare blood disorder ITP

Sweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the

X

Sobi gets EU nod for Doptelet in rare blood disorder ITP

https://pharmaphorum.com/news/sobi-gets-eu-nod-for-doptelet-in-rare-blood-disorder-itp/

Novartis’ severe aplastic anaemia drug fast-tracked by FDA

Novartis’ severe aplastic anaemia drug fast-tracked by FDA

The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.

X

Novartis’ severe aplastic anaemia drug fast-tracked by FDA

https://pharmaphorum.com/news/novartis-severe-aplastic-anaemia-fda/

Novartis adds Promacta to breakthrough status roll-call

Novartis adds Promacta to breakthrough status roll-call

Drug could get new indication based on NIH research

X

Novartis adds Promacta to breakthrough status roll-call

https://pharmaphorum.com/top-pharmaceutical-companies/novartis/fda-grants-novartis-drug-breakthrough-status-first-line-anaemia/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com